Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.

Malvern, Pennsylvania (ots/PRNewswire) -

Solstice Neurosciences, Inc. ("Solstice") announced the
appointment of Dennis L. Smith as President and Chief Executive
Officer. He will also continue to serve as Chairman to its Board of
Directors.

Mr. Smith brings unique specialty pharmaceutical industry
experience and expertise to Solstice that will be invaluable in
providing guidance, leadership, and strategies for growth as the
company continues to broaden its product portfolio globally and map
its strategy.

Mr. Smith has nearly 35 years of broad and global experience in
the pharmaceutical industry and most recently served as President and
Chief Executive Officer of INO Therapeutics LLC., a specialty
pharmaceutical company with strengths in development, marketing, and
sales of critical care drugs and drug/device combinations. Prior to
INO, Mr. Smith spent 15 years with DuPont Pharmaceutical Company,
where he served as President of U.S. Operations, Executive Vice
President of Europe, and Vice President and General Manager in
Canada, among numerous other positions at DuPont Pharmaceuticals and
DuPont Merck. Mr. Smith was also employed in management positions at
Baxter International and Sandoz Pharmaceuticals (now Novartis). Mr.
Smith is a graduate of Michigan State University and the Lake Forest
Graduate School of Business.

"I am excited to be joining Solstice at this time to work with the
management team and the Board of Directors to help lead and guide our
company's future strategic direction," said Mr. Smith.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a
biopharmaceutical company focused on the development, manufacturing,
sales and marketing of specialty products. Solstice's first product,
Myobloc(R) (Botulinum Toxin Type B) Injectable Solution, represents
the only botulinum toxin type B currently available to physicians and
patients. MYOBLOC is sold in the United States and approved in
Canada. It is also distributed and sold in the EU as NeuroBloc.
MYOBLOC is indicated for the treatment of patients with cervical
dystonia (CD) to reduce the severity of abnormal head position and
pain associated with CD. For more information about Solstice
Neurosciences, Inc., visit www.solsticeneuro.com.

Myobloc(R) and NeuroBloc(R) are registered trademarks of Solstice
Neurosciences, Inc.

Web site: http://www.solsticeneuro.com

ots Originaltext: Solstice Neurosciences, Inc.
Im Internet recherchierbar: http://www.presseportal.de

$story.getcontactHeadline()
Mike Pagnotta of Solstice Neurosciences, Inc., +1-866-220-5042,
michael.pagnotta@solsticeneuro.com